Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 22.7% in March

Jyong Biotech Ltd. (NASDAQ:MENS) was the recipient of a large decline in short interest during the month of March. As of March 13th, there was short interest totaling 288,865 shares, a decline of 22.7% from the February 26th total of 373,692 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average daily volume of 210,084 shares, the days-to-cover ratio is currently 1.4 days.

Jyong Biotech Trading Down 4.0%

Jyong Biotech stock opened at $1.94 on Friday. The business’s 50-day simple moving average is $2.21 and its 200-day simple moving average is $23.02. Jyong Biotech has a 52 week low of $1.43 and a 52 week high of $67.00.

Jyong Biotech (NASDAQ:MENS) last released its earnings results on Friday, January 9th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Institutional Trading of Jyong Biotech

A number of hedge funds have recently bought and sold shares of MENS. BNP Paribas Financial Markets acquired a new stake in Jyong Biotech in the 3rd quarter worth $67,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Jyong Biotech in the fourth quarter valued at about $49,000. Millennium Management LLC acquired a new stake in Jyong Biotech during the third quarter worth about $512,000. Man Group plc bought a new position in Jyong Biotech during the fourth quarter valued at about $56,000. Finally, Geode Capital Management LLC grew its holdings in shares of Jyong Biotech by 19.6% during the 4th quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after purchasing an additional 10,538 shares in the last quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jyong Biotech in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.